General
Preferred name
IDELALISIB
Synonyms
CAL-101 ()
GS-1101, CAL-101, GS-11CAL-101 ()
GS-1101 ()
CAL-101 (GS-1101) ()
CAL 101 ()
CT-CAL101 ()
Idealisib ()
GS 1101 ()
ZYDELIG ()
A-1138 ()
CAL101 ()
GS-11CAL-101 ()
CAL-101, GS-1101 ()
P&D ID
PD003400
CAS
870281-82-6
1146702-54-6
Tags
available
probe
drug
Approved by
EMA
FDA
First approval
2014
Drug Status
approved
Drug indication
Chronic lymphocytic leukaemia
Max Phase
Phase 4
Probe info
Probe selectivity
protein-selective
Probe type
P&D approved
calculated probe
experimental probe
Probe sources
Chemical Probes.org
High-quality chemical probes
Probe Miner (suitable probes)
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Idelalisib is highly selective and potent oral inhibitor of phosphoinositide 3-kinase (PI3K) δ. (GtoPdb)
MOA Inhibitor (Chemical Probes.org)
DESCRIPTION Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. (PKIDB)
DESCRIPTION inhibitor of PI3K catalytic subunit delta (Informer Set)
Cell lines
38
Organisms
0
Compound Sets
36
AdooQ Bioactive Compound Library
A10172
Axon Medchem Screening Library
2170
Cayman Chemical Bioactives
15279
ChEMBL Approved Drugs
CHEMBL2216870
ChEMBL Drugs
CHEMBL2216870
Chemical Probes.org
idelalisib
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
6741
Concise Guide to Pharmacology 2019/20
6741
Concise Guide to Pharmacology 2021/22
6741
Concise Guide to Pharmacology 2023/24
6741
Drug Repurposing Hub
DrugBank
DB09054
DrugBank Approved Drugs
DB09054
DrugCentral
4878
DrugCentral Approved Drugs
4878
DrugMAP
DM602WT
DrugMAP Approved Drugs
DM602WT
EU-OPENSCREEN Bioactive Compound Library
EOS100577
Guide to Pharmacology
6741
High-quality chemical probes
PD003400
Informer Set
660430
Kinase Inhibitors (best-in-class)
LINCS compound set
10204-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL2216870
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL2216870
MedChem Express Bioactive Compound Library
HY-13026
NCATS Inxight Approved Drugs
YG57I8T5M0
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
Probe Miner (suitable probes)
O00329/379664
ReFrame library
Selleckchem Bioactive Compound Library
CAL-101
TargetMol Bioactive Compound Library
T1894
T8651
Welcome Trust Cancer Drugs
238
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
415.16
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
5
cLogP
3.75
TPSA
101.38
Fraction CSP3
0.14
Chiral centers
1.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PIK3CD
PI3K delta
PI3Kδ
p110??
PIK3CA, PIK3CB, PIK3CD, PIK3CG
PI3K p110d inhibitor
Autophagy,PI3K
Compound status
clinical
Pathway
PI3K signaling
PI3K/Akt/mTOR signaling
Autophagy
PI3K/Akt/mTOR
Kinase group
Lipid
MOA
PI3K
lipid kinase inhibitor
Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors
PI3K inhibitor
Member status
member
Indication
chronic lymphocytic leukemia (CLL)
Target class
Kinase
Target subclass
PI3/PI4 family
Source data